DASHENLIN PHARMACEUTICAL GROUP CO., LTD.

News DaShenLin Pharmaceutical Group Co., Ltd.

Stocks

603233

CNE100002RG2

Drug Retailers

End-of-day quote Shanghai S.E. 26/10/2026			5-day change	1st Jan Change
19.00 ^CNY	+4.63%		-0.37%	+7.83%

10-23	DaShenLin Pharmaceutical Completes Maturity Redemption of Convertible Bonds	MT
10-14	Dashenlin Pharmaceutical to Redeem Dashen Convertible Bonds	MT

All News

Mentions Relevance

10-23	DaShenLin Pharmaceutical Completes Maturity Redemption of Convertible Bonds	MT
10-14	Dashenlin Pharmaceutical to Redeem Dashen Convertible Bonds	MT
10-12	DaShenLin Pharmaceutical to Pay H1 Dividend on Oct. 19	MT
09-02	Jefferies Adjusts DaShenLin Pharmaceutical Group's Price Target to 15 Yuan From 12 Yuan, Keeps at Underperform	MT
08-24	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-24	Dashenlin Pharma's Q1 Profit Rises 11%	MT
04-24	Dashenlin Pharma's 2025 Profit Jumps 35%, Revenue Rises 4%	MT
04-23	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Dashenlin pharmaceutical 2025 net profit up 35.0% y/y	RE
04-23	Sipai Health to Sell Stake in Pharmacy Operator to Dashenlin Pharmaceutical For RMB 51.7 Million	MT
04-22	DaShenLin Pharmaceutical Group Co., Ltd. signed a equity transfer agreement to acquire Sipai Zhihe Technology Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.	CI
30/10/25	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
28/08/25	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25/04/25	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25/04/25	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
15/10/24	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
20/09/24	Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024.	CI
18/09/24	DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on May 7, 2024, has closed with 6,722,254 shares, representing 0.59% for CNY 100.72 million.	CI
30/08/24	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
03/07/24	Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024.	CI
07/05/24	DaShenLin Pharmaceutical Group Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on April 1, 2024.	CI
28/04/24	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
28/04/24	DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05/03/24	Dashenlin Pharmaceutical Plans to Buy Back Up to 200 Million Yuan Worth of Shares	MT
23/01/24	DaShenLin Pharmaceutical Group Co., Ltd. cancelled the transaction announced on January 19, 2023	CI